Drug Trial Radar · NCT00074971
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Dec 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Oct 1999
Primary completion
Not stated
Study completion Dec 2004
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 25, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globatriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.
Conditions
- Fabry Disease
Interventions
Fabrazyme (agalsidase beta)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and efficacy
- Morphologic assessment of GL-3 inclusions in the capillary endothelium (vasculature) of the kidney
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of California San Fransisco
San Francisco, California
Northwest Oncology & Hematology Associates
Coral Springs, Florida
Children's Memorial Hospital
Chicago, Illinois
University of Iowa Hospital and Clinics
Iowa City, Iowa
Greater Baltimore Medical Center
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fetal Diagnostic and Imaging Center
Billings, Montana
University of New Mexico
Albuquerque, New Mexico
Mount Sinai School of Medicine
New York, New York
University of Rochester School of Medicine
Rochester, New York
Hart Family Practice
Hickory, North Carolina
Hematology/Oncology Associates of South Texas
San Antonio, Texas
University of Washington School of Medicine
Seattle, Washington
Hospital Edouard Herriot
Lyon, France
Hospital Europeen Georges Pompidou
Paris, France
Academisch Medisch Centrum
Amsterdam, Netherlands
University of Puerto Rico
San Juan, Puerto Rico
National Hospital for Neurology and Neurosurgery
London, United Kingdom
Hope Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.